Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cervarix co-administered with Engerix-B in healthy girls aged 9-15 years
2007-007783-14Phase 3Completed
- Sponsor
- GSK
- Start
- Feb 2008
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of human papillomavirus type 16 L1 capsid protein antigen and Hepatitis B vaccine in human papillomavirus infection and hepatitis B (HBV) (2 arms), sponsored by GSK. Primary endpoint: Anti-HBs seroprotection status at Month 7. Started Feb 2008; status: completed.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigenHepatitis B vaccine
03
Conditions
human papillomavirus infectionhepatitis B (HBV)
Beyond the preview
Go deeper on 2007-007783-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007783-14.